Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 294, Issue 5, 2008, Pages

  Bastarache, Julie A ^a,d   Wang, Ling ^a   Wang, Zhengming ^b   Albertine, Kurt H ^b   Matthay, Michael A ^c   Ware, Lorraine B ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fibrin deposition

Indexed keywords

FIBRIN; GAMMA INTERFERON; INTERLEUKIN 1BETA; PROCOAGULANT; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR;

ACUTE LUNG INJURY; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; CELL LYSATE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRIN DEPOSITION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ALVEOLUS EPITHELIUM; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; AGED; BLOOD CLOTTING; CELL CULTURE; CULTURE MEDIUM; LUNG ALVEOLUS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; RESPIRATORY TRACT MUCOSA;

ADULT; AGED; BLOOD COAGULATION; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; FEMALE; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; PULMONARY ALVEOLI; PULMONARY EDEMA; RESPIRATORY DISTRESS SYNDROME, ADULT; RESPIRATORY MUCOSA; THROMBOPLASTIN;

EID: 45849105171     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00372.2007     Document Type: Article

References (44)

1. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettila V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290: 238-247, 2003.
2. Albertine KH, Soulier MF, Wang Z, Ishizaka A, Hashimoto S, Zimmerman GA, Matthay MA, Ware LB. Fas and fas ligand are upregulated in pulmonary edema fluid and lung tissue of patients with acute lung injury and the acute respiratory distress syndrome. Am J Pathol 161: 1783-1796, 2002.
3. Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 86: 959-972, 2001.
4. Bastarache J, Wang L, Geiser T, Wang Z, Albertine K, Matthay M, Ware L. The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor. Thorax 62: 608-616, 2007.
5. Belaaouaj AA, Li A, Wun TC, Welgus HG, Shapiro SD. Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation. J Biol Chem 275: 27123-27128, 2000.
6. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149: 818-824, 1994.
7. Carr C, Bild GS, Chang AC, Peer GT, Palmier MO, Frazier RB, Gustafson ME, Wun TC, Creasey AA, Hinshaw LB, Taylor FB Jr, Galluppi GR. Recombinant E coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Circ Shock 44: 126-137, 1994.
8. Carraway MS, Welty-Wolf KE, Miller DL, Ortel TL, Idell S, Ghio AJ, Petersen LC, Piantadosi CA. Blockade of tissue factor: treatment for organ injury in established sepsis. Am J Respir Crit Care Med 167: 1200-1209, 2003.
9. Cella G, Bellotto F, Tona F, Sbarai A, Mazzaro G, Motta G, Fareed J. Plasma markers of endothelial dysfunction in pulmonary hypertension. Chest 120: 1226-1230, 2001.
10. Cella G, Cipriani A, Tommasini A, Rampin E, Sbarai A, Rocconi R, Mazzaro G, Luzzatto G. Tissue factor pathway inhibitor (TFPI) antigen plasma level in patients with interstitial lung disease before and after heparin administration. Semin Thromb Hemost 23: 45-49, 1997.
11. Cella G, Sbarai A, Mazzaro G, Vanzo B, Romano S, Hoppensteadt T, Fareed J. Plasma markers of endothelial dysfunction in chronic obstructive pulmonary disease. Clin Appl Thromb Hemost 7: 205-208, 2001.
12. Cirino G, Cicala C, Bucci MR, Sorrentino L, Maraganore JM, Stone SR. Thrombin functions as an inflammatory mediator through activation of its receptor. J Exp Med 183: 821-827, 1996.
13. Collados MT, Velazquez B, Borbolla JR, Sandoval J, Masso F, Montano LF, Guarner V. Endothelin-1 and functional tissue factor: a possible relationship with severity in primary pulmonary hypertension. Heart Vessels 18: 12-17, 2003.
14. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FB Jr, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 91: 2850-2860, 1993.
15. Cunningham AC, Hasty KA, Enghild JJ, Mast AE. Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8. Biochem J 367: 451-458, 2002.
16. de Moerloose P, De Benedetti E, Nicod L, Vifian C, Reber G. Procoagulant activity in bronchoalveolar fluids: no relationship with tissue factor pathway inhibitor activity. Thromb Res 65: 507-518, 1992.
17. Enkhbaatar P, Okajima K, Murakami K, Uchiba M, Okabe H, Okabe K, Yamaguchi Y. Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation. Am J Respir Crit Care Med 162: 1752-1759, 2000.
18. Greene KE, Wright JR, Steinberg KP, Ruzinski JT, Caldwell E, Wong WB, Hull W, Whitsett JA, Akino T, Kuroki Y, Nagae H, Hudson LD, Martin TR. Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Care Med 160: 1843-1850, 1999.
19. Hackeng TM, Sere KM, Tans G, Rosing J. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci USA 103: 3106-3111, 2006.
20. Hamuro T, Kido H, Asada Y, Hatakeyama K, Okumura Y, Kunori Y, Kamimura T, Iwanaga S, Kamei S. Tissue factor pathway inhibitor is highly susceptible to chymase-mediated proteolysis. FEBS J 274: 3065-3077, 2007.
21. Higuchi DA, Wun TC, Likert KM, Broze GJ Jr. The effect of leukocyte elastase on tissue factor pathway inhibitor. Blood 79: 1712-1719, 1992.
22. Idell S. Anticoagulants for acute respiratory distress syndrome: can they work? Am J Respir Crit Care Med 164: 517-520, 2001.
23. Idell S, Gonzalez K, Bradford H, MacArthur CK, Fein AM, Maunder RJ, Garcia JG, Griffith DE, Weiland J, Martin TR, McLarty J, Fair DS, Walsh PN, Colman RW. Procoagulant activity in bronchoalveolar lavage in the adult respiratory distress syndrome. Contribution of tissue factor associated with factor VII. Am Rev Respir Dis 136: 1466-1474, 1987.
24. Idell S, James KK, Levin EG, Schwartz BS, Manchanda N, Maunder RJ, Martin TR, McLarty J, Fair DS. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 84: 695-705, 1989.
25. Idell S, Koenig KB, Fair DS, Martin TR, McLarty J, Maunder RJ. Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 261: L240-L248, 1991.
26. Jesmin S, Gando S, Matsuda N, Sakuma I, Kobayashi S, Sakuraya F, Hattori Y. Temporal changes in pulmonary expression of key procoagulant molecules in rabbits with endotoxin-induced acute lung injury: elevated expression levels of protease-activated receptors. Thromb Haemost 92: 966-979, 2004.
27. Le Gall JR, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 270: 2957-2963, 1993.
28. T) method. Methods 25: 402-408, 2001.
29. Lum H, Malik AB. Regulation of vascular endothelial barrier function. Am J Physiol Lung Cell Mol Physiol 267: L223-L241, 1994.
30. Lwaleed BA, Bass PS. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol 208: 327-339, 2006.
31. Maroney SA, Cunningham AC, Ferrel J, Hu R, Haberichter S, Mansbach CM, Brodsky RA, Dietzen DJ, Mast AE. A GPI-anchored co-receptor for tissue factor pathway inhibitor controls its intracellular trafficking and cell surface expression. J Thromb Haemost 4: 1114-1124, 2006.
32. Matthay MA, Fukuda N, Frank J, Kallet R, Daniel B, Sakuma T. Alveolar epithelial barrier. Role in lung fluid balance in clinical lung injury. Clin Chest Med 21: 477-490, 2000.
33. Matthay MA, Wiener-Kronish JP. Intact epithelial barrier function is critical for the resolution of alveolar edema in humans. Am Rev Respir Dis 142: 1250-1257, 1990.
34. Moraes TJ, Chow CW, Downey GP. Proteases and lung injury. Crit Care Med 31: S189-S194, 2003.
35. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 138: 720-723, 1988.
36. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 264: 18832-18837, 1989.
37. Petersen LC, Bjorn SE, Nordfang O. Effect of leukocyte proteinases on tissue factor pathway inhibitor. Thromb Haemost 67: 537-541, 1992.
38. Sabharwal AK, Bajaj SP, Ameri A, Tricomi SM, Hyers TM, Dahms TE, Taylor FB Jr, Bajaj MS. Tissue factor pathway inhibitor and von Willebrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis. Am J Respir Crit Care Med 151: 758-767, 1995.
39. Wang L, Bastarache JA, Wickersham N, Fang X, Matthay MA, Ware LB. Novel role of the human alveolar epithelium in regulating intra-alveolar coagulation. Am J Respir Cell Mol Biol 36: 497-503, 2007.
40. Ware LB, Fang X, Matthay MA. Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 285: L514-L521, 2003.
41. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 342: 1334-1349, 2000.
42. Welty-Wolf KE, Carraway MS, Idell S, Ortel TL, Ezban M, Piantadosi CA. Tissue factor in experimental acute lung injury. Semin Hematol 38: 35-38, 2001.
43. Welty-Wolf KE, Carraway MS, Miller DL, Ortel TL, Ezban M, Ghio AJ, Idell S, Piantadosi CA. Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am J Respir Crit Care Med 164: 1988-1996, 2001.
44. Welty-Wolf KE, Carraway MS, Ortel TL, Ghio AJ, Idell S, Egan J, Zhu X, Jiao JA, Wong HC, Piantadosi CA. Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure. Am J Physiol Lung Cell Mol Physiol 290: L21-L31, 2006.